• Overview
  • Eligibility
  • More info
  • Locations

A Phase II Trial of Bryostatin 1 in Ovarian Cancer Administered by Weekly 24 Hour Intravenous Infusion (NCT00004008)

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have ovarian epithelial cancer that has not responded to previous chemotherapy.
  • Drug: bryostatin 1
    Ages eligible for Study
    18 Years and older
    Genders eligible for Study
    Female
    Accepts Healthy Volunteers
    No
    OBJECTIVES:

    - Evaluate the antitumor activity and toxicity of bryostatin 1 in patients with platinum resistant ovarian epithelial cancer.

    - Determine the response rate in patients treated with this regimen.

    OUTLINE: This is a multicenter study.

    Patients receive bryostatin 1 IV over 24 hours. Treatment repeats weekly for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable or regressive disease may receive additional treatment.

    Patients are followed for at least 4 weeks after treatment, then every 3 months.

    PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.

    4 locations

    United Kingdom (4)
    • Christie Hospital N.H.S. Trust
      Manchester, England, United Kingdom, M20 4BX
    • Oxford Radcliffe Hospital
      Oxford, England, United Kingdom, 0X3 9DU
    • Weston Park Hospital
      Sheffield, England, United Kingdom, S1O 2SJ
    • Royal Infirmary
      Glasgow, Scotland, United Kingdom, G4 0SF
    Status:
    completed
    Type:
    Interventional
    Phase:
    Start:
    30 June, 1999
    Updated:
    24 June, 2013
    Participants:
    0
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!